 Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 5 | 1 | 6 | | 2004 | 3 | 1 | 4 | | 2005 | 8 | 0 | 8 | | 2006 | 6 | 4 | 10 | | 2007 | 10 | 2 | 12 | | 2008 | 7 | 5 | 12 | | 2009 | 4 | 3 | 7 | | 2010 | 5 | 2 | 7 | | 2011 | 4 | 4 | 8 | | 2012 | 4 | 1 | 5 | | 2013 | 5 | 0 | 5 | | 2014 | 8 | 1 | 9 | | 2015 | 11 | 4 | 15 | | 2016 | 11 | 2 | 13 | | 2017 | 8 | 7 | 15 | | 2018 | 9 | 3 | 12 | | 2019 | 8 | 6 | 14 | | 2020 | 11 | 2 | 13 | | 2021 | 8 | 1 | 9 | | 2022 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Eckel RH, Bruce KD. Statins, gut microbiome, LDL-C, glucose intolerance: Personalized medicine timely? Med (N Y). 2022 06 10; 3(6):355-357.
-
Schwartz GG, Giugliano RP. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Curr Opin Lipidol. 2022 06 01; 33(3):147-159.
-
McRae M, Low Wang CC. Macrovascular Complications. Prim Care. 2022 Jun; 49(2):255-273.
-
White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Jukema JW, Loy M, Pagidipati N, Pordy R, Ristic AD, Zeiher AM, Wojdyla DM, Steg PG. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022 04 19; 43(16):1554-1565.
-
Meckley AL, Militello M, Sivesind TE, Schilling L, Dellavalle RP. From the Cochrane Library: Statins and Fibrates for Preventing Melanoma. Dermatology. 2022; 238(4):668-669.
-
Ruff CT, Koren MJ, Grimsby J, Rosenbaum AI, Tu X, Karathanasis SK, Falloon J, Hsia J, Guan Y, Conway J, Tsai LF, Hummer BT, Hirshberg B, Kuder JF, Murphy SA, George RT, Sabatine MS. LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2021 12; 41(12):3005-3014.
-
Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, Orringer CE, Saseen JJ, Smith SC, Sperling LS, Virani SS. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
-
Peterson GG, Pu J, Magid DJ, Barterian L, Kranker K, Barna M, Conwell L, Rose A, Blue L, Markovitz A, McCall N, Markovich P. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021 09 01; 6(9):1050-1059.
-
Francis P, Forman L. HATs Off to Clot Blockers: A Potential New Role for Statins After Transplantation. Liver Transpl. 2021 10; 27(10):1375-1377.
-
Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021 06 11; 128(12):1868-1884.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|